IP Library Granted Patent US 10,525,088
Granted Patent B2
US 10,525,088 · App. 15/314,149 · Granted Jan 7, 2020

Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria

Inventors: Masaya Kanayama (Tokyo, JP); Kyoko Tazumi (Tokyo, JP)
Assignee: Kirin Holdings Kabushiki Kaisha
A61K35/744A23L2/52A23L33/135A61K9/0056A61K9/0095A61K31/047A61K31/20A61K31/23A61K31/7016A61K31/7024A61K39/39A61P37/04C12N1/20A23V2002/00A23Y2240/41A61K39/00A61K2039/55594
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,525,088
App. No.
15/314,149
Granted
Jan 7, 2020
Kind
B2
Abstract

It is an object of the present invention to provide a lactic acid bacterial immunopotentiating activity-increasing composition that increases the immunopotentiating activity of lactic acid bacteria having immunopotentiating activity; and a method for increasing the immunopotentiating activity of lactic acid bacteria using the composition; and a composition comprising both of lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition, wherein the immunopotentiating activity of the lactic acid bacteria is increased. The present invention relates to a composition comprising lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition comprising an ester compound of a polyol and a saturated fatty acid as an active ingredient.

Claims (14)

1. A composition comprising lactic acid bacteria having immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition comprising an ester compound of a polyol and a saturated fatty acid as an active ingredient, wherein the ratio of the concentration of the ester compound of the polyol and the saturated fatty acid to the concentration of the lactic acid bacteria having the immunopotentiating activity is in the range of 0.5 to 50:1 and wherein the concentration of the ester compound is in the range of 0.05 to 0.5% (w/v), and the lactic acid bacteria having the immunopotentiating activity are of Lactococcus lactis JCM5805 strain.

2. The composition according to claim 1 , wherein the immunopotentiating activity of the lactic acid bacteria having the immunopotentiating activity is increased compared to the immunopotentiating activity of the lactic acid bacteria which are not contacted with the ester compound of the polyol and the saturated fatty acid.

3. The composition according to claim 1 , wherein the composition is a beverage or food.

4. The composition according to claim 1 , wherein the polyol is selected from the group consisting of monoglycerol, polyglycerol, and sucrose.

5. The composition according to claim 1 , wherein the saturated fatty acid is selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and behenic acid.

6. The composition according to claim 1 , wherein the ester compound of the polyol and the saturated fatty acid is not modified with any organic acid.

7. The composition according to claim 1 , wherein the lactic acid bacteria having the immunopotentiating activity induce interferon production of an interferon-producing cell.

8. A method of increasing immunopotentiating activity of lactic acid bacteria having immunopotentiating activity, comprising contacting the lactic acid bacteria having immunopotentiating activity with a lactic acid bacterial immunopotentiating activity-increasing composition comprising an ester compound of a polyol and a saturated fatty acid as an active ingredient, wherein the ratio of the concentration of the ester compound of the polyol and the saturated fatty acid to the concentration of the lactic acid bacteria having the immunopotentiating activity is in the range of 0.5 to 50:1 and wherein the concentration of the ester compound is in the range of 0.05 to 0.5% (w/v), and the lactic acid bacteria having the immunopotentiating activity are of Lactococcus lactis JCM5805 strain, and wherein the immunopotentiating activity of the lactic acid bacteria contacted with the ester compound of the polyol and the saturated fatty acid is increased compared to the immunopotentaiting activity of the lactic acid bacteria which are not contacted with the ester compound of the polyol and the saturated fatty acid.

9. The method according to claim 8 , wherein the polyol is selected from the group consisting of monoglycerol, polyglycerol, and sucrose.

10. The method according to claim 8 , wherein the saturated fatty acid is selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and behenic acid.

11. The method according to claim 8 , wherein the ester compound of the polyol and the saturated fatty acid is not modified with any organic acid.

12. The method according to claim 8 , wherein the lactic acid bacteria having the immunopotentiating activity induce interferon production of an interferon-producing cell.

13. The method of claim 8 , wherein the contacting is by culturing the lactic acid bacteria having the immunopotentiating activity in the presence of the lactic acid bacterial immunopotentiating activity-increasing composition.

14. The method of claim 8 , wherein the contacting is by adding the lactic acid bacterial immunopotentiating activity-increasing composition to a liquid containing the lactic acid bacteria having the immunopotentiating activity.

Assignments (2)
MERGER Recorded Aug 2, 2019
From: KIRIN COMPANY, LIMITED
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 049950/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: KANAYAMA, MASAYA; TAZUMI, KYOKO
To: KIRIN COMPANY, LIMITED
Reel/Frame 040424/0503 →
Priority Claims (1)
JP 2014-113529 · May 30, 2014 · national
Continuity (1)
Related Publication 20170189458A1 · Jul 6, 2017